At the BIO Patient and Health Advocacy Summit last year, I learned a great deal about the FDA’s unprecedented approach to “Patient-Focused Drug Development,” and realized just how far advocacy relations has come during my 20 years of practice in health care PR. The way patients are being perceived by the pharmaceutical, diagnostics, insurance, hospital and biotech industries is dramatically changing. As health communications professionals, we need to understand exactly how these unprecedented shifts impact the way we counsel our clients, and construct and implement integrated communications programs.

Continue reading " Eli Lilly, Novartis, FDA, the National Health Council and Top Advocacy Groups Discuss Tectonic Shifts in Patient Communications "